Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

12. August 2025 09:30 ET | Quelle: Artios Pharma

Artios Pharma Appoints Michael T. Andriole as CEO and Director to Advance Alnodesertib (ART0380) into Late-stage Development

Mike Andriole brings approximately 25 years of experience in the biopharmaceutical industry and a successful track record of delivering new first-in-class oncology therapies in indications of high...
29. April 2025 15:35 ET | Quelle: Artios Pharma

Artios Pharma Reports Differentiated Clinical Activity in STELLA Phase 1/2a Study for Lead Program ART0380 at the American Association for Cancer Research (AACR) Annual Meeting 2025

ART0380 in combination with low-dose irinotecan demonstrated a 50% confirmed overall response rate (cORR) in patients with Ataxia-Telangiectasia Mutated (ATM)-negative1 solid tumors at the...
15. April 2025 08:00 ET | Quelle: Artios Pharma

Artios Pharma Announces Details of Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025

CAMBRIDGE, United Kingdom and NEW YORK, April 15, 2025 – Artios Pharma Limited (“Artios”), a clinical-stage biotech company led by pioneers of DNA damage response (“DDR”) drug development, today...
19. Dezember 2024 08:00 ET | Quelle: Artios Pharma

Artios Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, United Kingdom and NEW YORK, December 19, 2024 – Artios Pharma Limited (“Artios”), a clinical-stage biotech company led by pioneers of DNA damage response (“DDR”) drug development, today...

Vorherige Seite